Biomarkers of Muscle Catabolism During Hospitalization

Abstract

Muscle catabolism is a critical concern in hospitalized patients, contributing to adverse outcomes including prolonged recovery, increased morbidity, and mortality. Identifying reliable biomarkers of muscle breakdown during hospitalization is essential for early detection, risk stratification, and intervention. This review synthesizes current evidence on biochemical and molecular markers indicative of muscle catabolism, discusses their clinical relevance, and explores the evolving landscape of diagnostic and therapeutic approaches in the inpatient setting. Particular emphasis is placed on pathophysiological mechanisms, risk factors, diagnostic strategies, and recent advances in biomarker research.

Introduction

Muscle catabolism, defined as the breakdown of skeletal muscle proteins, is a prevalent complication during hospitalization, particularly among critically ill, elderly, and immobilized patients. The resultant loss of muscle mass and function, collectively termed hospital-acquired sarcopenia, is associated with reduced functional capacity and poor clinical outcomes. Early detection of muscle catabolism relies on sensitive and specific biomarkers to guide clinical management. Recent studies have highlighted the importance of integrating biomarker assessment into routine hospital care to mitigate the deleterious effects of muscle wasting.

Epidemiology / Disease Burden

Hospitalized patients are at significant risk for rapid skeletal muscle loss, with studies showing up to 2% daily reduction in muscle mass in critically ill individuals. Incidence is particularly high among patients in intensive care units (ICUs), those with sepsis, trauma, or prolonged bed rest, and the elderly. Muscle catabolism is a key contributor to hospital-acquired disability, extended length of stay, increased rehospitalization rates, and elevated healthcare costs. The burden is amplified in patients with preexisting comorbidities such as chronic kidney disease, heart failure, and cancer, underscoring the need for vigilant monitoring and early intervention.

Pathophysiology

The pathogenesis of muscle catabolism during hospitalization is multifactorial. Systemic inflammation, metabolic stress, immobilization, and inadequate nutrition converge to drive proteolysis. Key molecular pathways include upregulation of ubiquitin-proteasome and autophagy-lysosome systems, increased expression of muscle-specific E3 ubiquitin ligases (MuRF1, Atrogin-1), and dysregulated anabolic signaling (e.g., suppressed IGF-1/Akt/mTOR pathway). Hormonal perturbations, such as elevated cortisol and decreased testosterone or growth hormone, further exacerbate muscle breakdown. The interplay between cytokines (IL-6, TNF-α), oxidative stress, and mitochondrial dysfunction accelerates the loss of muscle proteins, reinforcing the need for mechanistically informed biomarker selection.

Risk Factors

Several risk factors heighten susceptibility to muscle catabolism during hospitalization. These include advanced age, preexisting sarcopenia, chronic diseases (e.g., diabetes, chronic obstructive pulmonary disease), critical illness, sepsis, trauma, immobility, and inadequate protein-energy intake. Polypharmacy, particularly corticosteroids and neuromuscular blockers, can augment catabolic processes. Genetic predispositions and baseline nutritional status also modulate individual risk profiles, highlighting the importance of comprehensive patient assessment.

Clinical Features

Clinically, muscle catabolism presents as progressive weakness, reduced mobility, and functional decline. Physical findings may include muscle wasting, decreased grip strength, and impaired activities of daily living. In severe cases, respiratory muscle involvement can compromise ventilatory function, prolonging mechanical ventilation dependency. Subtle early manifestations are often overlooked without objective assessment, underscoring the imperative for biomarker-guided surveillance to detect subclinical muscle loss.

Diagnosis

The diagnosis of muscle catabolism in the hospital setting is challenging due to the limitations of direct muscle mass measurement. Biomarkers provide a valuable adjunct. Serum creatinine and urea are traditional but nonspecific indicators, influenced by renal function and hydration status. More specific biomarkers include 3-methylhistidine (3-MH), a product of myofibrillar protein degradation, and urinary creatinine excretion. Circulating levels of muscle-specific enzymes (e.g., creatine kinase, lactate dehydrogenase) may reflect acute muscle injury but lack chronicity specificity. Emerging biomarkers such as plasma myostatin, GDF-15, and circulating microRNAs (miR-1, miR-206) offer promise for early and dynamic assessment. Integration of biochemical markers with imaging modalities (ultrasound, CT, MRI) and functional tests (handgrip strength, gait speed) enables comprehensive evaluation.

Treatment & Management

Management strategies target both the underlying drivers and the consequences of muscle catabolism. Early mobilization and physiotherapy are cornerstone interventions, promoting anabolic signaling and reducing proteolysis. Optimizing nutritional support, particularly adequate protein and energy intake, is critical. Pharmacologic options under investigation include anabolic agents (testosterone, selective androgen receptor modulators), anti-inflammatory therapies, and myostatin inhibitors. Close monitoring of biomarkers can guide therapy intensity and duration, enabling personalized care. Multidisciplinary collaboration among physicians, dietitians, and physiotherapists is essential for effective management.

Recent Advances / Emerging Therapies

Recent advances in biomarker discovery have leveraged high-throughput omics technologies to identify novel targets such as circulating exosomes, non-coding RNAs, and metabolomic profiles associated with muscle catabolism. Point-of-care assays for rapid biomarker quantification are in development, facilitating bedside risk stratification. Clinical trials are evaluating interventions such as myostatin antagonists and nutraceuticals with anti-catabolic properties. Integration of digital health tools, including wearable devices and remote muscle monitoring, is transforming real-time assessment and intervention.

Guideline Recommendations

Current clinical guidelines emphasize early identification and prevention of muscle catabolism in hospitalized patients. The European Society for Clinical Nutrition and Metabolism (ESPEN) and American Society for Parenteral and Enteral Nutrition (ASPEN) recommend routine assessment of muscle mass and strength, prioritizing at-risk populations. Biomarker monitoring is encouraged as an adjunct to clinical evaluation, with protocol-driven approaches for nutritional and rehabilitative interventions. Ongoing research is expected to refine biomarker panels and inform evidence-based algorithms for inpatient care.

Conclusion

Biomarkers of muscle catabolism are integral to the early detection, diagnosis, and management of muscle wasting in hospitalized patients. Advances in molecular and biochemical marker research hold promise for improving patient outcomes through personalized, mechanism-based interventions. Clinicians should remain vigilant for risk factors and employ a multimodal approach to assessment and therapy. As the field evolves, incorporation of validated biomarkers into standard practice will be key to mitigating the burden of muscle catabolism in the inpatient setting.